<PAGE>
- - --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934
FILING NO. 1 FOR THE MONTH OF APRIL, 2000
Visible Genetics Inc.
--------------------------
(Exact name of Registrant)
700 Bay Street, Suite 1000, Toronto ON, Canada M5G 1Z6
------------------------------------------------------
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F
Form 20-F X Form 40-F
--- ---
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
--- ---
- - ------------------------------------------------------------------------------
<PAGE>
VISIBLE GENETICS INC.
On April 4, 2000 Visible Genetics Inc. (the "Company") completed a
follow-on public offering of 2,000,000 common shares at $38 per share. All of
the shares were sold by the Company. The Company may sell up to an additional
300,000 shares to cover underwriters' over-allotments. The net proceeds, after
fees and expenses, will be used for working capital and general corporate
purposes. The managing underwriters of the offering were FleetBoston Robertson
Stephens Inc., PaineWebber Incorporated, Warburg Dillon Read LLC and Roth
Capital Partners, Inc.
A copy of the final prospectus may be obtained directly from the Prospectus
Department of one of the managing underwriters: FleetBoston Robertson Stephens
Inc., 555 California St., Suite 2600, San Francisco, CA, 94104; PaineWebber
Incorporated, 1285 Avenue of the Americas, New York, NY, 10019; Warburg Dillon
Read LLC, 299 Park Avenue, New York, NY, 10171; Roth Capital Partners, Inc.,
4350 LaJolla Village Drive, San Diego, CA, 92122.
This Form 6-K contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to risks, uncertainties and
other factors which may cause the Company's results to differ materially from
expectations. These include risks relating to the ability to obtain regulatory
approval, market acceptance of genotyping and the Company's products and other
risks detailed from time to time in the Company's SEC filings, including its
most recent Annual Report on Form 20-F. These forward-looking statements speak
only as of the date hereof. The Company disclaims any intent or obligation to
update these forward-looking statements.
The Company hereby incorporates by reference this Form 6-K into the
Company's Registration Statements on Form F-3, and into the prospectuses
contained therein, (File Nos. 333-67607, 333-68939, 333-91155, 333-94649 and
333-32258) and the Company's outstanding Registration Statements on Form S-8.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
VISIBLE GENETICS INC.
Date: April 5, 2000 By: /s/ Richard T. Daly
-------------------
Name: Richard T. Daly
Title: President and CEO
